All In Biotech

Drug Trial Radar · NCT06072768

Dynamic Treatment Regiments for Glucocorticoid Tapering

Using SMART Design to Develop Dynamic Treatment Regimens for Glucocorticoid Tapering

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 9, 2023

Primary completion

Mar 1, 2029

Study completion Mar 1, 2030

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
University of Michigan
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at different patient characteristics, including levels of inflammation in the body, differences in the way the brain processes sensory information, and certain hormone levels, to help researchers better understand why different people have these different responses to steroid tapering. The hypotheses include: * Greater or equal to ( ) 30% of participants in each arm will develop taper intolerance (either subjective, objective, or both) during the study period * Greater or equal to 60% of participants will reduce Glucocorticoid dose by at least 5 Milligrams per day during the study period

Conditions

  • Rheumatoid Arthritis

Interventions

  • 15-day taper prednisoneDrug

    The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.

  • 150-day taper prednisoneDrug

    The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with subjective taper intoleranceTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)
  2. Number of participants with objective taper intoleranceTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)
  3. Net glucocorticoid dose reductionTime frame: Day 30 (15-day taper) or day 180 (150-day taper group)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    Ann Arbor, Michigan · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.